There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.
Abstract
<p class="first" id="d2301344e67">Cancer immunotherapies, including checkpoint inhibitors
and adoptive cell therapy,
manipulate the immune system to recognize and attack cancer cells. These therapies
have the potential to induce durable responses in multiple solid and hematologic malignancies
and thus have transformed treatment algorithms for numerous tumor types. Cancer immunotherapies
lead to unique toxicity profiles distinct from the toxicities of other cancer therapies,
depending on their mechanism of action. These toxicities often require specific management,
which can include steroids and immune-modulating therapy and for which consensus guidelines
have been published. This review will focus on the toxicities of checkpoint inhibitors
and chimeric antigen receptor T cells, including pathophysiology, diagnosis, and management.
</p>